STRN

STRN (striatin) is a brain-enriched, calmodulin-binding WD-repeat protein that localizes to the somato-dendritic compartment and dendritic spines of neurons, where its features point to a role as a scaffold in dendritic Ca2+ signaling (PMID:9693043). Its most extensively characterized activity, however, is as the 5' partner in the oncogenic STRN-ALK fusion: a chromosomal rearrangement joins STRN exon 3 to ALK exon 20, retaining the STRN coiled-coil domain that drives constitutive ALK kinase dimerization and activation independent of upstream stimuli (PMID:24613930, PMID:24475247, PMID:30225407). This fusion is sufficient to transform thyroid cells, conferring thyroid-stimulating hormone-independent proliferation and tumor formation in xenografts, with all effects dependent on ALK kinase activity (PMID:24613930, PMID:24475247). In transgenic mice, thyroid-specific STRN-ALK expression produces poorly differentiated thyroid carcinoma with loss of thyroglobulin and E-cadherin, and combined p53 loss drives stepwise progression to anaplastic carcinoma with lung metastases (PMID:30125543, PMID:31298630). Mechanistically, STRN-ALK activates MAPK, JAK/STAT3, and PI3K/AKT/mTOR signaling and downregulates thyroid differentiation and iodine-metabolism genes including Slc5a5/NIS, Foxe1, Tg, and Duox1/2, causing loss of membrane NIS and reduced radioiodine uptake that is reversed by ALK or MEK inhibition (PMID:36585857). Outside the fusion context, STRN has been implicated as a regulator of epithelial-mesenchymal transition in hepatocellular carcinoma (PMID:32280692).

1. 1998 Medium

   Established the identity and basic properties of STRN, defining it as a calmodulin-binding WD-repeat protein with neuronal, dendritic localization—framing it as a candidate scaffold in dendritic calcium signaling.

   Evidence cDNA cloning, sequencing, FISH chromosomal mapping, and northern blot expression analysis

   PMID:9693043

   Open questions at the time

   • No direct demonstration of the calcium-signaling function inferred from localization
   • Scaffold binding partners not identified in this work
   • No structural model of the WD-repeat or coiled-coil regions
2. 2014 High

   Identified the STRN-ALK fusion and showed that the STRN coiled-coil domain mediates constitutive ALK dimerization and kinase activation, answering how a non-kinase scaffold becomes oncogenic.

   Evidence RNA-seq fusion discovery, proliferation/transformation assays, nude mouse xenografts, coiled-coil mutagenesis, and ALK inhibitor treatment; fusion junction confirmed by array-CGH, RT-PCR, and Sanger sequencing

   PMID:24475247 PMID:24613930

   Open questions at the time

   • Does not address whether wild-type STRN function contributes to oncogenesis
   • Downstream effector pathways not dissected in this study
3. 2018 High

   Demonstrated in vivo that STRN-ALK alone is sufficient to initiate thyroid carcinogenesis and dedifferentiation, moving beyond cell-based transformation to organismal causation.

   Evidence Thyroglobulin promoter-driven STRN-ALK transgenic mice with histology, IHC, and goitrogen treatment

   PMID:30125543

   Open questions at the time

   • Tumors remained poorly differentiated rather than fully anaplastic, indicating cooperating events were unresolved
   • Molecular pathway downstream of the fusion not mapped here
4. 2019 High

   Established genetic epistasis between STRN-ALK and p53 loss in driving progression to anaplastic carcinoma with metastasis, defining the cooperating event needed for full malignancy.

   Evidence Compound transgenic mice with ultrasound imaging, histology, IHC, RNA-seq, and qRT-PCR

   PMID:31298630

   Open questions at the time

   • Does not establish which transcriptional programs mediate the progression
   • Therapeutic vulnerability of advanced tumors not tested
5. 2023 High

   Dissected the signaling consequences of STRN-ALK, linking fusion activity to MAPK/JAK-STAT3/PI3K-AKT-mTOR activation and to loss of NIS-mediated radioiodine uptake reversible by kinase inhibition—explaining the dedifferentiation and radioiodine resistance phenotype.

   Evidence Doxycycline-inducible STRN-ALK in PCCL3 cells with transcriptomics, Western blot, immunofluorescence, 131I uptake assay, and ALK/MEK/JAK inhibitor rescue

   PMID:36585857

   Open questions at the time

   • Which pathway predominantly drives NIS loss not fully resolved among the three activated arms
   • Findings in rat thyroid cell line require validation in human disease context
6. 2022 Low

   Proposed a non-fusion role for STRN as a downstream node of STK25 regulating hepatic lipid metabolism and EMT, extending STRN function into metabolic regulation.

   Evidence Co-IP, Western blot, wound healing/Transwell assays, xenografts, and STRING interaction prediction in HCC cells

   PMID:34986838

   Open questions at the time

   • Pathway placement relies partly on database prediction rather than direct mechanism
   • STK25-STRN interaction not validated reciprocally or by structural methods
   • Single lab without mechanistic follow-up
7. 2020 Low

   Implicated wild-type STRN as a regulator of EMT in hepatocellular carcinoma, suggesting a scaffold function in tumor invasion independent of ALK fusion.

   Evidence siRNA knockdown and overexpression in Huh7 cells with migration/invasion assays, EMT-marker Western blots, and tissue IHC

   PMID:32280692

   Open questions at the time

   • No upstream or downstream molecular mechanism beyond EMT-marker correlation
   • Single cell line and single lab
   • Effect on proliferation/apoptosis was absent, limiting interpretation
8. 2025 Low

   Synthesized evidence positioning STRN as a multifunctional scaffold modulating kinases, phosphatases, and calcium pathways with links to vascular reactivity and salt-sensitive blood pressure.

   Evidence Review synthesizing prior experimental findings (no new primary data)

   PMID:40752421

   Open questions at the time

   • No new primary experimental data
   • Cardiovascular and phosphatase-scaffold roles not mechanistically resolved within this corpus

• The normal physiological function of wild-type STRN as a calmodulin-binding scaffold—its phosphatase/kinase partners and its role in dendritic calcium signaling—remains uncharacterized at the mechanistic level in this corpus.
• No reconstituted scaffold complex or defined enzymatic partners in the timeline
• Neuronal calcium-signaling role inferred from localization but not functionally tested
• Link between native scaffold function and oncogenic fusion biology unexplored